Claude

The Full Story

Centene's narrative over the past three years is the story of a new CEO inheriting a sprawling, acquisition-built empire and attempting to simplify it – only to collide with a simultaneous unraveling of three of its four business segments. Sarah London took over from the late Michael Neidorff in March 2022 with a clear "Value Creation Plan" centered on divestitures, margin expansion, and operational discipline. Through 2023-2024, the plan appeared to be working: adjusted EPS grew from $5.78 to $6.68 to $7.17, Marketplace membership surged, and the company executed over $7 billion in buybacks. Then 2025 happened. Marketplace risk adjustment revenue collapsed, Medicaid medical costs accelerated, the OBBBA reshaped the regulatory landscape, and the company withdrew guidance in July, triggering a 40% single-day stock decline. A $6.7 billion goodwill impairment followed. Adjusted EPS fell from $7.17 to $2.08. Management credibility, painstakingly built, was severely damaged in a single quarter.

The Narrative Arc

The arc follows a textbook pattern: inherit complexity, simplify aggressively, show early results, then get hit by external forces while the simplification is still incomplete. London's Value Creation Plan was real – she sold over a dozen businesses, cut the SG&A ratio from 9.0% to 7.4%, and drove Marketplace from 2.1M to 5.5M members. But the plan assumed a favorable regulatory environment (enhanced APTCs, stable Medicaid funding) that evaporated in 2025.

The HBR chart tells the real story. From a stable 87.7% in 2022-2023, it crept to 88.3% in 2024 and then spiked to 91.9% in 2025. Each 100 basis points of HBR deterioration on $172B in premiums represents roughly $1.7 billion in additional medical costs. The 360 bps move from 2024 to 2025 effectively erased the company's operating margin.

What Management Emphasized – and Then Stopped Emphasizing

Dropped themes: The "Value Creation Plan" was the centerpiece of every communication in 2022-2023. By 2025, the term vanished entirely from the 10-K. It was replaced by vaguer language about "value creation initiatives." Stock buybacks went from $3.0B in 2024 to $400M in 2025, a quiet retreat that signals the company now needs cash to shore up reserves rather than reward shareholders.

Escalated themes: Medical cost trend went from background noise to the dominant narrative. The 2025 10-K devotes extensive space to "accelerated increase in medical cost trend," citing behavioral health, home health, and high-cost drugs. The OBBBA, which did not exist until July 2025, became a top-three risk factor overnight. D-SNP alignment – serving dual-eligible members through integrated Medicaid/Medicare plans – emerged as the new long-term growth thesis.

Quiet pivots: Marketplace shifted from being the company's growth engine and margin hero to a source of significant concern. In 2024, Commercial gross margin was $7.7B. In 2025, it fell to $5.1B – a $2.6B decline driven by "lower estimated risk adjustment revenue and increased Marketplace medical costs." The 2026 re-pricing in states covering 95% of Marketplace membership is an implicit admission that the 2025 pricing was wrong.

Risk Evolution

The risk profile has fundamentally shifted. In FY2023, the dominant risks were legacy issues: international operations (Operose, Circle Health), real estate impairments from the post-COVID footprint reduction, and Medicare Star ratings that had deteriorated. These were self-inflicted, manageable problems.

By FY2025, the risk landscape is dominated by external, systemic forces: federal legislation (OBBBA), medical cost trend acceleration across all segments, the expiration of enhanced APTCs, and Marketplace risk adjustment volatility. These are not problems management can solve through operational discipline alone. The PBM transition risk, which disrupted 2024 cash flow ($154M operating cash flow vs. $8.1B in 2023), has largely resolved – 2025 operating cash flow recovered to $5.1B.

The contract loss risk has also intensified. Centene was not selected for the Florida Children's Medical Services program (contract ending September 2026) and is protesting procurement results in Georgia and Texas – two of its largest Medicaid markets.

How They Handled Bad News

Centene faced three major episodes of bad news over this period. Their handling reveals a pattern of initial candor followed by underestimation of the problem's duration.

Episode 1: Medicare Star Ratings Deterioration (2022-2024). When Star ratings fell in October 2022, management acknowledged the problem and booked a $250M premium deficiency reserve in Q4 2023. They launched a "multi-year plan to build and improve quality." By October 2024, they could show progress: 55% of MA membership in plans rated 3.5 stars or higher, up from 23%. By October 2025, that reached 60%. This was handled well – the problem was identified, quantified, and addressed with measurable improvement.

Episode 2: Medicaid Redeterminations (2023-2025). In early 2023, management framed redeterminations as a manageable, time-limited event. They emphasized their "best positioned" status with the Ambetter Marketplace product to capture transitioning members. The redetermination process dragged on far longer than expected. Traditional Medicaid membership fell from 14.3M (2022) to 12.8M (2023) to 11.4M (2024) to 10.9M (2025). Management kept saying they were "working with state partners to match rates to acuity" – a phrase repeated in essentially identical wording across all three years – while gross margin in Medicaid fell from $8.6B (2023) to $6.2B (2024) to $5.7B (2025).

Episode 3: The July 2025 Guidance Withdrawal. This was the most damaging event. In July 2025, management withdrew full-year guidance, citing "significantly higher estimated aggregate market morbidity" reducing risk adjustment revenue. The stock fell 40% in a single day. Sarah London later told Fortune: "It's hard not to feel like pulling guidance and cutting the stock in half is a failure." The transparency was admirable, but the implication – that management did not see the morbidity shift coming until mid-year – raised serious questions about the company's data and analytics capabilities, which had been a core part of the London narrative.

Guidance Track Record

The guidance track record splits cleanly into two chapters. In FY2023-2024, management consistently beat or met its own targets. The SG&A ratio improvement was delivered. The Medicare Star recovery progressed measurably. The PBM transition was completed. These were genuine operational wins.

Then FY2025 destroyed the track record. Initial guidance of greater than $6.00 adjusted EPS was withdrawn entirely in July, and actual results came in at $2.08 – a 65% miss relative to the initial target. This was not a narrow miss attributable to timing or one-offs. It was a fundamental misread of the Marketplace risk pool and medical cost trajectory.

Credibility Score: 5 out of 10. The score reflects a weighted view: strong operational execution on divestitures, SG&A, and Star ratings (which would merit a 7-8) offset by the catastrophic FY2025 guidance miss (which alone would be a 3). The decision to withdraw guidance promptly rather than drip-feed bad news prevents a lower score.

What the Story Is Now

The current story is simpler but more stretched than it was in 2024. Here is what has been de-risked, what remains fragile, and what investors should believe versus discount.

De-risked:

The portfolio simplification is nearly complete. International operations are gone. Magellan Health is being divested. TRICARE expired. What remains is the core managed care triad: Medicaid (57% of revenue), Commercial/Marketplace (21%), and Medicare (19%). The SG&A reduction from 8.9% to 7.4% appears structural and durable. Medicare Star ratings are genuinely improving – 60% of membership at 3.5+ stars, with 20% at 4 stars, up from 23% just two years ago. The PBM transition disruption that crushed 2024 cash flow has resolved.

Still stretched:

The Marketplace thesis is under severe pressure. Enhanced APTCs expired at the end of 2025. The OBBBA adds repayment requirements for mis-estimated income and restricts special enrollment period subsidies. Management acknowledged needing corrective pricing actions in 95% of Marketplace states for 2026. Membership could decline meaningfully. The fundamental question is whether Centene can price accurately for a sicker, smaller Marketplace pool.

Medicaid faces structural headwinds from OBBBA work requirements, more frequent redeterminations, and provider tax adjustments. Management's repeated promise to "work with state partners to match rates to acuity" has been made for three consecutive years while Medicaid gross margin has fallen by $3 billion. The rate-to-acuity matching is happening, but slower than cost escalation.

The chart reveals the critical dynamic: Commercial margin surged from $5.0B to $7.7B in 2024, masking the $2.4B decline in Medicaid. When Commercial collapsed back to $5.1B in 2025, there was nothing to offset the continued Medicaid erosion. Medicare is the only segment showing margin improvement, driven by PDP membership growth (from 4.6M to 8.1M members) and the IRA-driven premium yield increase.

What to believe: The D-SNP opportunity is real. CMS regulations requiring dual-eligible integration by 2030 play directly to Centene's strengths as the largest Medicaid insurer with overlapping Medicare footprints. The 12 million dual-eligible population represents genuine long-term upside. The ICHRA opportunity (employer-sponsored insurance disruption) is early-stage but potentially large.

What to discount: The 2026 guidance of greater than $3.00 adjusted EPS implies a near-50% recovery from 2025. This requires Marketplace re-pricing to work in a membership-declining environment, Medicaid rates to catch up to costs, and no new regulatory shocks. Given the 2025 experience, significant execution risk remains. The stock at $37 (forward P/E of approximately 12x on 2026 guidance) prices in a recovery but leaves limited margin of safety if the recovery falls short.